antigen-presenting cell

(redirected from Antigen presenting cell)
Also found in: Wikipedia.

antigen-presenting cell

a cell that can break down protein antigens into peptides and present the peptides, in conjunction with major HLA complex class II molecules, on the cell surface, where they can interact with T cell receptors. Macrophages are one type of antigen-presenting cell.

antigen-presenting cell

Abbreviation: APC
A cell that breaks down antigens and displays their fragments on surface receptors next to major histocompatibility complex molecules. This presentation is necessary for some T lymphocytes that are unable to recognize soluble antigens. Macrophages are the primary antigen-presenting cells, but B cells and dendritic cells also can act as APCs.
See: T cell; macrophage processing cell
See also: cell

antigen-presenting cell

A cell, such as a macrophage, a B cell or a dendritic cell, that presents processed antigenic peptides and MHC class II molecules to the T cell receptor on CD4 T cells.
References in periodicals archive ?
and the international Ludwig Institute for Cancer Research (LICR) have announced a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex's Antigen Presenting Cell (APC) Targeting Technology.
The expanded peptide-specific regulatory cells shut down the autoimmune attack by preventing aggressive autoimmune cells from being stimulated by either the peptide contained in the vaccine or by any other type 1 diabetes autoantigen presented simultaneously on the same antigen presenting cell.
The method involves the loading of an antigen presenting cell with at least one tumor associated T-cell epitope attached to an immunoglobulin backbone to form an Ig-peptide molecule ("IgNP") followed by administration the IgNP in conjunction with MCT-465, a dsRNA TLR agonist adjuvant therapeutic.
SEATTLE, March 3 /PRNewswire-FirstCall/ -- Dendreon Corporation announced the publication of a manuscript titled, "CD54 is a surrogate marker of antigen presenting cell activation" in Cancer Immunology, Immunotherapy.
Recently, MultiCell filed the patent application entitled, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," which covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
Michael Morse of Duke University presented data from a Phase 1, dose-escalating study of CDX-1307, the Company's lead cancer program using its proprietary Antigen Presenting Cell (APC) targeting technology, in a poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
In an newsletter article released today, SmallCapInsights addresses MultiCell's most recent patent announcementCo"Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," and provides investors with background on the Company and opinion on its progress and potential.
The patent filing, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
The deletion of these genes provides a proprietary vaccine platform which combines very efficient antigen delivery to, and optimal stimulation of, this key class of antigen presenting cell.
The patent claims artificial antigen presenting cell compositions that are broadly applicable to treatment methodologies capable of eliciting up- or down-modulation of an immune response in patients with a need for such modulation.
Antigen Presenting Cell Based Immunotherapy Targeting HER2/Neu Positive Solid Tumors: Results of a Phase 1 Study of APC8024.
CD40, a receptor on the surface of antigen presenting cells of the immune system, plays a fundamental role in the activation of both innate and adaptive immune system mechanisms.